NeuroPace, Inc. (NPCE)

NASDAQ: NPCE · Real-Time Price · USD
8.72
-0.04 (-0.51%)
Jul 31, 2025, 2:56 PM - Market open
-0.51%
Market Cap285.84M
Revenue (ttm)84.31M
Net Income (ttm)-24.81M
Shares Out 32.80M
EPS (ttm)-0.83
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume54,049
Open8.74
Previous Close8.76
Day's Range8.61 - 8.78
52-Week Range5.45 - 18.98
Beta1.94
AnalystsStrong Buy
Price Target16.33 (+87.38%)
Earnings DateAug 12, 2025

About HES

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet and patient data management system; and nSight Platform, which facil... [Read more]

Sector Healthcare
IPO Date Apr 22, 2021
Employees 184
Stock Exchange NASDAQ
Ticker Symbol NPCE
Full Company Profile

Financial Performance

In 2024, NeuroPace's revenue was $79.91 million, an increase of 22.14% compared to the previous year's $65.42 million. Losses were -$27.14 million, -17.64% less than in 2023.

Financial numbers in BGN Financial Statements

Analyst Summary

According to 6 analysts, the average rating for NPCE stock is "Strong Buy." The 12-month stock price target is $16.33, which is an increase of 87.38% from the latest price.

Price Target
$16.33
(87.38% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

NeuroPace Announces Strategic CFO Transition

Appoints Patrick F. Williams as Chief Financial Officer Williams Brings a Track Record of Leading Medical Device Public Companies as CFO Rebecca Kuhn Departing Company and Will Remain in Advisory Role...

5 weeks ago - GlobeNewsWire

NPCE Investors Have Opportunity to Join NeuroPace, Inc. Fraud Investigation with the Schall Law Firm

LOS ANGELES , June 24, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of NeuroPace, Inc. ("Ne...

5 weeks ago - PRNewsWire

Bronstein, Gewirtz & Grossman, LLC Is Investigating NeuroPace, Inc. (NPCE) And Encourages Shareholders to Connect

NEW YORK CITY, NY / ACCESS Newswire / June 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of NeuroPace, Inc. ("NeuroPace" or "the Company") (NA...

6 weeks ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against NeuroPace, Inc. (NPCE) And Encourages Shareholders to Reach Out

NEW YORK CITY, NY / ACCESS Newswire / June 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of NeuroPace, Inc. ("NeuroPace" or "the Company") (NA...

7 weeks ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against NeuroPace, Inc. (NPCE) and Encourages Shareholders to Learn More About the Investigation

NEW YORK CITY, NY / ACCESS Newswire / June 11, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of NeuroPace, Inc. ("NeuroPace" or "the Company") (NA...

7 weeks ago - Accesswire

NeuroPace, Inc. (NPCE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

NEW YORK CITY, NY / ACCESS Newswire / June 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of NeuroPace, Inc. ("NeuroPace" or "the Company") (NA...

7 weeks ago - Accesswire

NeuroPace, Inc. (NPCE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

NEW YORK CITY, NY / ACCESS Newswire / June 9, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of NeuroPace, Inc. ("NeuroPace" or "the Company") (NAS...

7 weeks ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Is Investigating NeuroPace, Inc. (NPCE) And Encourages Investors to Connect

NEW YORK CITY, NY / ACCESS Newswire / June 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of NeuroPace, Inc. ("NeuroPace" or "the Company") (NAS...

7 weeks ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Encourages NeuroPace, Inc. (NPCE) Stockholders to Inquire about Securities Investigation

NEW YORK CITY, NY / ACCESS Newswire / June 6, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of NeuroPace, Inc. ("NeuroPace" or "the Company") (NAS...

7 weeks ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against NeuroPace, Inc. (NPCE) and Encourages Investors to Learn More About the Investigation

NEW YORK CITY, NY / ACCESS Newswire / June 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of NeuroPace, Inc. ("NeuroPace" or "the Company") (NAS...

2 months ago - Accesswire

NeuroPace Secures Up to $75 Million in Debt Financing

MOUNTAIN VIEW, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that...

2 months ago - GlobeNewsWire

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against NeuroPace, Inc. (NPCE) And Encourages Stockholders to Reach Out

NEW YORK CITY, NY / ACCESS Newswire / June 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of NeuroPace, Inc. ("NeuroPace" or "the Company") (NAS...

2 months ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Is Investigating NeuroPace, Inc. (NPCE) And Encourages Stockholders to Connect

NEW YORK CITY, NY / ACCESS Newswire / June 2, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of NeuroPace, Inc. ("NeuroPace" or "the Company") (NAS...

2 months ago - Accesswire

NeuroPace, Inc. (NPCE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

NEW YORK CITY, NY / ACCESS Newswire / June 1, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of NeuroPace, Inc. ("NeuroPace" or "the Company") (NAS...

2 months ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against NeuroPace, Inc. (NPCE) and Encourages Stockholders to Learn More About the Investigation

NEW YORK CITY, NY / ACCESS Newswire / May 30, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of NeuroPace, Inc. ("NeuroPace" or "the Company") (NAS...

2 months ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Encourages NeuroPace, Inc. (NPCE) Investors to Inquire about Securities Investigation

NEW YORK CITY, NY / ACCESS Newswire / May 29, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of NeuroPace, Inc. ("NeuroPace" or "the Company") (NAS...

2 months ago - Accesswire

Why Is NeuroPace Stock Falling After Epilepsy Treatment Study Data?

NeuroPace, Inc. NPCE released preliminary primary endpoint one-year results of the two-year NAUTILUS study evaluating safety and effectiveness of the RNS System for drug-resistant idiopathic generaliz...

2 months ago - Benzinga

NeuroPace Announces Preliminary Results from One-Year Data in NAUTILUS Study

-- NeuroPace has completed the primary endpoint analysis of the one-year data from the first and only clinical study to evaluate neuromodulation therapy for idiopathic generalized epilepsy

2 months ago - GlobeNewsWire

NeuroPace, Inc. (NPCE) Q1 2025 Earnings Call Transcript

NeuroPace, Inc. (NASDAQ:NPCE) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants Jeremy Feffer - LifeSci Advisors Joel Becker - Chief Executive Officer Rebecca Kuhn - Chief...

2 months ago - Seeking Alpha

NeuroPace Reports First Quarter 2025 Financial Results

-- Reported record quarterly revenue of $22.5 million in Q1 2025, driven by increasing market demand for core RNS System products -- -- Increased full-year 2025 revenue guidance to $93 to $97 million ...

2 months ago - GlobeNewsWire

NeuroPace Provides Update on Tariff Status

-- Minimal expected impact to operations and financial results -- -- Company to report first quarter 2025 financial results on May 13, 2025 --

3 months ago - GlobeNewsWire

NeuroPace Announces Data From a Long-Term Post-Approval Study of the RNS System in Focal Epilepsy at the 2025 AAN Annual Meeting

Three-year data from the largest FDA-reviewed prospective neuromodulation study of safety and effectiveness in drug-resistant focal epilepsy1 Long-term seizure reduction with a median reduction of 82%...

4 months ago - GlobeNewsWire

NeuroPace Announces Upcoming Oral Presentation of Data from the Long-Term Post-Approval Study of the RNS System at the 2025 AAN Annual Meeting

MOUNTAIN VIEW, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, will be attending a...

4 months ago - GlobeNewsWire

NeuroPace Announces Refocusing of Product Portfolio

-- Beginning of Wind Down of Stereo EEG (SEEG) Distribution Relationship in Q4 2025 -- -- Maintaining 2025 Revenue Guidance -- -- No Change to Long-Range Plan Expectations of Cash Flow Breakeven by th...

4 months ago - GlobeNewsWire

NeuroPace to Present at the 24th Annual Needham Virtual Healthcare Conference

MOUNTAIN VIEW, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced tha...

4 months ago - GlobeNewsWire